The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

The tyrosine kinase inhibitor (TKI) drug class is a prominently used option in the treatment of
various cancers. Safety evaluation of these drugs has shown evidence of cardiotoxicity of …

甲磺酸阿帕替尼片是口服小分子抗血管生成抑制剂新药, 主要通过高度选择性地抑制血管内皮
生长因子受体-2 (VEGFR-2) 酪氨酸激酶的活性, 阻断血管内皮生长因子(VEGF) …

Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical
benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab …

The use of novel targeted anticancer agents has led to overall improvement in the prognosis
of many patients affected by various malignancies, but has also been associated with an …

Despite the clinical implication and high incidence of bone and spinal metastases, the
molecular mechanisms behind prostate cancer metastasis to bone and spine are not well …

In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus
bevacizumab, this novel combination has become the preferred first-line standard of care for …

Gastric cancer is one of the most frequent malignancies worldwide. Despite improvements in
diagnosis and therapy, the overall prognosis remains poor. In the last decade, several anti …

Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may
prolong survival in ovarian and cervical cancer when given in combination with …

Significance: Angiogenesis inhibition with humanized antibodies targeting vascular
endothelial growth factor (VEGF) or orally active small tyrosine kinase inhibitors targeting …